Lobbying registration dated 2026-03-10
Registrant: Paul Petrelli
Client: Gilead Sciences Canada
Targeted institutions:
Canadian Institutes of Health Research (CIHR)
Treasury Board Of Canada Secretariat (TBS)
Public Services and Procurement Canada (PSPC)
Indigenous Services Canada (ISC)
Global Affairs Canada (GAC)
Patented Medicine Prices Review Board (PMPRB)
Intergovernmental Affairs Secretariat (IGA)
Finance Canada (FIN)
Crown-Indigenous Relations and Northern Affairs Canada (CIRNAC)
House of Commons
Public Health Agency of Canada (PHAC)
Privy Council Office (PCO)
Senate of Canada
Health Canada (HC)
Correctional Service of Canada (CSC)
Prime Minister's Office (PMO)
Innovation, Science and Economic Development Canada (ISED)
CUSMA Secretariat
Immigration, Refugees and Citizenship Canada (IRCC)
Acts: Patent Act
Government funding received:
Lobbying activity details:
Federal Government First Nations and Inuit Health Branch program with respect to health services. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations
Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.
Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.
Policy measures to ensure security of
drug supply in Canada and preserve
Canada's attractiveness for
biopharmaceutical launches, including
in response to foreign pricing
regulations.
Free Trade agreements as they relate to the biopharmaceutical industry
Policy and Programs
Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19.
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector